The FDA recently released updated guidance, titled “Rare Diseases: Considerations for the Development of Drugs and Biological Products,” emphasizing the…
In recent years, the adoption of alternative funding programs (AFPs) among self-funded employer-sponsored plans has risen rapidly. However, few employers…
A recent study published in the New England Journal of Medicine examined the pricing practices of hospitals participating in the…
The Senate 340B Working Group is soliciting additional stakeholder input on key longstanding issues surrounding the Medicare 340B program. The…
This month, the Movement Disorder Policy Coalition (MDPC) released a new policy paper, “Parkinson’s Disease: Improving Treatment While Working Toward…
Senate Commerce Committee leaders, Maria Cantwell and Chuck Grassley, along with 12 lawmakers, are requesting an update from the Federal…
Cell and gene therapies (CGTs) have provided new optimism for patients living with diseases previously considered untreatable. These groundbreaking treatments…
Florida’s plan to import prescription drugs from Canada is facing a potential setback as Canadian officials are expressing concerns about…
On January 17, 2024, the Centers for Medicare & Medicaid Services (CMS) finalized the CMS Interoperability and Prior Authorization Final…
On January 22, 2024, Aimed Alliance published two new resources on prescription drug affordability boards (PDABs). These boards, established at…